

News Release

Newport Beach, CA - October 21, 2016



ImmunogenX®

ImmunogenX Invited to Present at the Pharmaceutical Strategy Conference

The company presents details of its upcoming clinical trial plan

ImmunogenX, a biopharmaceutical company focused on the diagnosis and treatment of celiac disease, today announced that it was invited to present at the opening session of the Pharmaceutical Strategy Conference held in New York, NY on September 28-30, 2016. This venue provided the opportunity to present previously unreported data and analyses from the Phase 2b clinical trial completed in September 2015 by Alvine Pharmaceuticals and provide details of ImmunogenX's upcoming final Phase 2 trial. The trial studied the digestive enzyme mixture latiglutenase, which is a drug taken with meals that degrades inadvertent gluten in the stomach. ImmunogenX acquired the therapeutic asset from Alvine in February 2016. The Phase 2b trial was the most comprehensive trial conducted to date for celiac disease therapy. These results provide a plausible clinical/regulatory path forward to bring this therapeutic treatment to those suffering from celiac disease.

"ImmunogenX is committed to bettering the lives of patients with celiac disease. We are very enthusiastic about the post-hoc analysis of Phase 2b that revealed a consistent reduction of symptom severity for those seropositive patients taking latiglutenase," said Dr. Jack A. Syage, CEO of ImmunogenX. "A key breakthrough in the re-analysis was the realization that symptoms of inadvertent gluten ingestion manifest as flare events rather than persistent ongoing symptoms. These new analyses substantiate latiglutenase as an effective and safe treatment for celiac disease patients."

About ImmunogenX

ImmunogenX (a subsidiary of Immunogenics LLC) is a clinical-stage company founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors in celiac disease research. The company recently acquired Latiglutenase (ALV003) for celiac disease therapy, which is currently in Phase 2 clinical trials. ImmunogenX is also developing a minimally-invasive diagnostic tool for celiac disease management (CypCel) based on a clinically relevant metabolic marker compound that can assess the state of recovery of a celiac patient adhering to a gluten-free diet or other treatment. For food safety, ImmunogenX is pioneering advanced mass spectrometry methods to identify and measure physiologically relevant gluten peptide sequences found in wheat, barley, and rye and has developed the first multiplexed analytical method to detect and quantify trace levels of gluten and other allergens in food and consumer products.

www.immunogenx.com

For further information please contact

Matthew Dickason, COO

949 679-0900

mdickason@immunogenx.com